Simcere Pharmaceutical Group to Acquire Additional 10% of Equity Interest in Shangdong Simcere Medgenn Bio-Pharmaceutical Co., Ltd.

Simcere Pharmaceutical Group to Acquire Additional 10% of Equity Interest in Shangdong Simcere Medgenn Bio-Pharmaceutical Co., Ltd.

June 14, 2007

    NANJING, China, June 14 /Xinhua-PRNewswire/ -- Simcere
Pharmaceutical Group (NYSE: SCR), a leading manufacturer
and supplier of branded generic pharmaceuticals in China,
and the manufacturer of innovative anti-cancer medication
Endu, today announced that it has entered into an agreement
to acquire an additional 10% equity interest in Shandong
Simcere Medgenn Bio-Pharmaceutical Co. Ltd., or Shandong
Simcere Medgenn, (formerly known as Yantai Medgenn Co.
Ltd.)  Simcere will pay approximately RMB 26.83 million in
cash for the 10% stake, and its total equity interest in
Shandong Simcere Medgenn will reach 90% upon completion of
the transaction.

    Mr. Jinsheng Ren, chairman and CEO of Simcere,
commented, "We are very pleased to acquire an
additional 10% equity interest in Shandong Simcere Medgenn.
We continue to be encouraged by the positive reactions from
doctors and patients towards Endu's application. We believe
Endu has significant market potential and have increased our
stake in Shandong Simcere Medgenn accordingly because we
believe that it will bring additional value to our
shareholders. Our R&D team has initiated multiple
Endu-related research projects.  We plan to further
strengthen and accelerate our collaboration with domestic
and international research institutions to explore
potential indications for Endu, including the treatment of
liver cancer, stomach cancer, colon cancer and breast
cancer."

    About Simcere Pharmaceutical Group 

    Simcere Pharmaceutical Group is a leading manufacturer
and supplier of branded generic pharmaceuticals in the
rapidly growing China market.  In recent years, Simcere has
focused its strategy on the development of first-to-market
generic and innovative pharmaceuticals, and has introduced
a first-to-market generic anti-stroke medication under the
brand name Bicun and an innovative anti-cancer medication
under the brand name Endu.  Simcere currently manufactures
and sells 35 pharmaceutical products including antibiotics,
anti-cancer medication and anti-stroke medication and is the
exclusive distributor of three additional pharmaceuticals
that are marketed under its brand names. Simcere
concentrates its research and development efforts on the
treatment of diseases with high incidence and/or mortality
rates and for which there is a clear demand for more
effective pharmacotherapy such as cancer, strokes,
osteoporosis and infectious diseases. For more information
about Simcere, please visit http://www.simcere.com .

   Safe Harbor Statement

   This press release contains forward-looking statements.
These statements constitute "forward-looking"
statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and as defined
in the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as "anticipate,"
"believe," "estimate,"
"expect," "forecast,"
"intend," "may," "plan,"
"project," "predict,"
"should" and "will" and similar
expressions.  These forward-looking statements are based
upon management's current views and expectations with
respect to future events and are not a guarantee of future
performance. Furthermore, these statements are, by their
nature, subject to a number of risks and uncertainties that
could cause actual performance and results to differ
materially from those discussed in the forward-looking
statements as a result of a number of factors. Further
information regarding these and other risks is included in
Simcere's filing with the U.S. Securities and Exchange
Commission at http://www.sec.gov . Simcere does not
undertake any obligation to update any forward-looking
statement, except as required under applicable law.

    For investor and media inquiries, please contact:

     In China:
      Eric Wang-Lam Cheung
      Vice President, Investor Relations
      Simcere Pharmaceutical Group
      Tel:   [phone] x8898  
      Email: [e-mail] 

     In the United States:  
      Ashley Zandy
      Brunswick Group LLC
      Tel:   [phone]
      Email: [e-mail]